<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594838</url>
  </required_header>
  <id_info>
    <org_study_id>8157-3/1</org_study_id>
    <nct_id>NCT03594838</nct_id>
  </id_info>
  <brief_title>Evaluation of HCV Viremia Testing Approaches Among PWID in Georgia</brief_title>
  <acronym>HEAD-Start</acronym>
  <official_title>Feasibility, Acceptability, Effectiveness and Cost-analysis of Models of HCV Viremia Testing for Confirmation and Cure Among People Who Inject Drugs (PWID): the HEAD*-Start Trial in Georgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foundation for Innovative New Diagnostics, Switzerland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The National Center for Disease Control and Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Research Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Foundation for Innovative New Diagnostics, Switzerland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate two novel approaches to improve access to Hepatitis C virus (HCV)
      confirmatory viremia testing. Both approaches are &quot;Harm reduction site-based (HRS)&quot; because
      HCV viremia testing will be initiated and test results will be provided at the HRSs. These
      approaches will be compared to the current standard of care (control) in which
      anti-HCV-positive individuals must travel to a HCV treatment centre for HCV viremia testing.
      The investigators hypothesize that improving access to viremia testing improves linkage to
      care and reduces loss to follow-up among those who screen anti-HCV-positive.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A major step in identifying HCV infected individuals in Georgia has already been implemented
      by providing rapid anti-HCV testing for people who inject drugs (PWID) at HRS. However,
      access to HCV confirmatory viremia testing remains limited as PWID must be referred to
      treatment centers for testing.

      Two novel approaches to improve access to HCV viremia testing will be evaluated.

      In the first approach, participants with a positive anti-HCV test will have blood drawn and
      HCV RNA test performed at the HRS. Test results will be provided the same day (or the
      following day if the participant is unable to wait for results) at the HRS.

      In the second approach participants with a positive anti-HCV test will have blood drawn at
      the HRS. The blood will be processed on site and a plasma sample shipped to a central
      laboratory for viremia testing. Test results will be communicated to the participants by HRS
      staff at a follow-up visit as soon as the results are available.

      In both groups, participants who test positive will be referred to a treatment centre for
      further assessments and subsequent treatment initiation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 21, 2018</start_date>
  <completion_date type="Actual">July 21, 2020</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A non-randomized 3 arm-interventional study at eight HRSs to evaluate two novel approaches of HCV viremia testing and compare them to the current standard of care. The HRS will be assigned to one of three study arms.
Six HRSs will provide HCV viremia testing on-site using one of two approaches as follows and two HRS will refer patients off-site for testing (current standard of care).
The three arms will be compared to determine differences in the proportion of anti-HCV-positive patients that receive HCV viremia test results.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HCV care cascade</measure>
    <time_frame>6 months</time_frame>
    <description>1.1. Proportion of participants with a positive HCV viremia test who complete each subsequent step in the HCV care cascade</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HCV confirmatory viremia test result receipt</measure>
    <time_frame>1-30 days</time_frame>
    <description>Proven superiority (with a margin of 10%) of the proportion of participants with a positive anti-HCV test who receive results of an HCV confirmation of viremia test in each intervention arm separately, compared to referral-based testing (SOC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Entry into HCV care</measure>
    <time_frame>1-14 days</time_frame>
    <description>Proven superiority (with a margin of 10%) of the proportion of participants with positive anti-HCV test who submit a blood sample for viremia testing in each intervention arm separately, compared to referral based testing (SOC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Initiation Fraction</measure>
    <time_frame>4 weeks</time_frame>
    <description>Proportion of participants with positive HCV viremia test who initiate hepatitis treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HCV confirmatory viremia test result receipt by intervention</measure>
    <time_frame>1-14 day</time_frame>
    <description>Proportion of participants with a positive anti-HCV test who receive results of an HCV confirmation of viremia test using decentralized HCV RNA testing compared to centralized HCV core antigen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of HCV confirmatory viremia testing approach</measure>
    <time_frame>6 months</time_frame>
    <description>Costs of HCV viremia testing approaches from a health service and patient perspective</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operational performance of HCV confirmatory viremia testing</measure>
    <time_frame>6 months</time_frame>
    <description>Testing volumes at the harm reduction sites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uptake of HCV confirmatory viremia testing</measure>
    <time_frame>4-8 weeks</time_frame>
    <description>Facilitators and barriers of getting an HCV confirmatory viremia test as perceived by participants and health care workers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attitudes and preferences of participants for HCV confirmatory viremia testing as assessed on a Likert scale</measure>
    <time_frame>4-8 weeks</time_frame>
    <description>Willingness of participants to get HCV confirmatory viremia testing as assessed on the Likert Scale of 'strongly agree' (0), 'agree' (1), 'neither agree nor disagree' (2), 'disagree' (3), 'strongly disagree' (4)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1672</enrollment>
  <condition>Hepatitis C, Chronic</condition>
  <arm_group>
    <arm_group_label>Decentralized testing approach</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Harm reduction site HCV viremia testing approach A. Four HRS will conduct blood draw and point-of-service (decentralized) HCV RNA testing, and results will be provided at the HRS on the same or the following day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Centralized testing approach</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Harm reduction site HCV viremia testing approach B. Two sites will collect blood samples on site and transport them to a reference (centralized) laboratory for HCV viremia testing. Results will be provided at a follow-up visit to the HRS as soon as results are available.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Current standard of care. Patients who screen anti-HCV positive at HRS will be referred to HCV treatment centers for HCV RNA testing, and results will be provided at a follow-up visit to the treatment center.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HCV viremia testing approaches</intervention_name>
    <description>Blood draw and HCV viremia testing is done at point of service (Intervention A) Blood draw at point of service and HCV viremia testing at a centralized laboratory (Intervention B)</description>
    <arm_group_label>Centralized testing approach</arm_group_label>
    <arm_group_label>Decentralized testing approach</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. People who inject drugs attending for care and needle provision at harm reduction
             sites.

             Inclusion criteria:

               -  Any history of injection drug use (IDU)

               -  Age â‰¥18 years

               -  Anti-HCV-positive on rapid diagnostic test performed at the HRS

               -  Eligible for the Georgia HCV State Program

               -  Living in the catchment area served by the HRS

               -  No plans to move out of the catchment area during the next 6 months

               -  Willing and able to give informed consent

             Exclusion criteria:

               -  Tested HCV RNA-positive from April 2015

               -  Pregnancy (self-report)

               -  Currently on treatment for hepatitis C

               -  Unable to provide a blood sample

          2. HRS staff involved in HCV testing and care:

             Inclusion criteria

               -  Provide HCV services at HRS from screening through linkage to care.

          3. Laboratory staff performing HCV viremia testing at the HRSs, Lugar Centre and
             Treatment centres:

        Inclusion criteria:

          -  Perform HCV viremia testing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonjelle Shilton</last_name>
    <role>Study Director</role>
    <affiliation>Find</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Irma Khonelidze</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Centre for Disease Control, Georgia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imedi Harm Reduction Site</name>
      <address>
        <city>Batumi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Step to the Future Harm Reduction Site</name>
      <address>
        <city>Gori</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Way Harm Reduction Site</name>
      <address>
        <city>Kutaisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Vector Harm Reduction Site</name>
      <address>
        <city>Rust'avi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akeso Harm Reduction Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Vector Harm Reduction Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Way Harm Reduction Site</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xenon Harm Reduction Site</name>
      <address>
        <city>Zugdidi</city>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Georgia</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 13, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV viremia testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Viremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

